This biotech company develops a novel therapy to treat antimicrobial-resistant skin infections and non-healing wounds. Their technology simultaneously clears AMR infections, promotes wound healing, and identifies genes contributing to non-healing wounds, particularly in diabetic skin.
Funding
Funding not disclosed
Founders
Product
Problem
Antimicrobial resistance is a growing global threat, rendering many antibiotics ineffective against bacterial infections, especially in vulnerable populations like diabetics. Diabetic individuals are particularly susceptible to non-healing wounds and skin infections, which can lead to limb amputation or death when antibiotics fail. Current therapies often lack the ability to address both the infection and the underlying wound-healing deficiency.
Solution
KoshKey Sciences is developing a novel RNA interference (RNAi) therapy to simultaneously combat antimicrobial-resistant (AMR) infections and promote wound healing, particularly in diabetic patients. The therapy leverages the company's research into the molecular mechanisms that cause impaired wound healing and increased susceptibility to infections in diabetic skin. By identifying and silencing the genes responsible for non-healing wounds and recurrent infections, the RNAi therapy aims to restart the healthy wound-healing program in skin keratinocytes. This approach facilitates pathogen clearance and accelerates the overall wound-healing process, offering a comprehensive solution for infected and non-healing ulcers.
Target Audience
The primary target audience includes diabetic individuals suffering from non-healing wounds and antimicrobial-resistant skin infections, as well as healthcare providers specializing in wound care and infectious diseases.
Features
- Topical RNAi therapy designed to address antimicrobial-resistant skin infections and non-healing wounds.
- Targets specific genes responsible for impaired wound healing and increased susceptibility to infection in diabetic skin.
- Aims to activate the wound-healing program and antimicrobial response in skin keratinocytes.
- Designed for both pathogen clearance and accelerated wound healing.
- Based on in-house research identifying molecular mechanisms behind diabetic skin's vulnerability.